Ann: FDA approval of HALOETTE, a generic version of NUVARING, page-23

" another product we could actually lose money on " . Until company reports net profit think we're unlikely to see decent share improvement . Company obviously makes good money but at the end of the day its all about how much what we're left with , net profit . With our track record of net loses and buying costly products/ leases which have yet to prove their worth not hard to see why share value pretty much going nowhere but side way's . Until there's real evidence our costly products/ leases likely to pay off even if they do within a reasonable time frame , company needs to keep generating enough income to be able to afford carrying these products that hopefully makes money for us eventually . Hard to see net profit anytime soon ( hope I'm wrong) just hoping company reports impressive turnover and an acceptable level of debt + net profit expected not too far away .